Riskpilot← Back to searchSign inGet full accessONCOTYPE ApS
APSActiveCVR 20655305Rosenvængets Allé 6A, 1.Computer programming activities · NACE 6210Est. 19983 employees
Revenue 2025
DKK 1,2M
0% vs 2024
EBITDA margin
-0.4%
-131% vs 2024
Equity ratio
10.6%
Financial strength
Net profit 2025
DKK -40K
-199% vs 2024
| Revenue | DKK 1,2M | +0% |
| EBITDA | DKK -5K | -131% |
| Net profit | DKK -40K | -199% |
| Total assets | DKK 631K | -16% |
| Equity | DKK 67K | -37% |
| Employees | 3 | — |
Legal name
ONCOTYPE ApS
CVR number
20655305
Legal form
Anpartsselskab
NACE code
6210 · Computer programming activities
Founded
1. januar 1998
Share capital
DKK 125.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at yde assistance i forbindelse med design og anden virksomhed i relation med internettet samt IT-virksomhed iøvrigt.
Address
Rosenvængets Allé 6A, 1.
Phone
+4533320403
Email
mortens@oncotype.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1.249 | 1.230 | 1.509 | 1.203 | 1.199 |
| Staff expenses | -1.214 | -1.182 | -1.443 | -1.186 | -1.205 |
| EBITDA | 35 | 48 | 66 | 17 | -5 |
| Depreciation & amort. | -25 | -27 | -16 | -12 | -12 |
| EBIT | 10 | 21 | 50 | 5 | -17 |
| Net financials | -5 | -11 | -33 | -18 | -24 |
| Profit before tax | 5 | 10 | 17 | -12 | -41 |
| Tax | 1 | 5 | 11 | 1 | -1 |
| Net profit | 4 | 6 | 6 | -13 | -40 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 758 | 841 | 843 | 755 | 631 |
| Equity | 108 | 114 | 120 | 107 | 67 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 647 | 720 | 705 | 630 | 547 |
| Total debt | 647 | 720 | 705 | 630 | 547 |
EBITDA margin
-0.4%
This company
15.8%
Market median
-103% vs market
20212025
Equity ratio
10.6%
This company
38.2%
Market median
-72% vs market
20212025
Return on equity
-59.9%
This company
18.4%
Market median
-426% vs market
20212025
Net profit margin
-3.3%
This company
8.1%
Market median
-141% vs market
20212025
Asset turnover
1.90×
This company
1.12×
Market median
+70% vs market
20212025
Debt / equity
8.47×
This company
0.62×
Market median
-1266% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
PA Management | Management | 1998 – 1998 |
TB Management | Management | 1998 – 2001 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 50–66.65% | 50–66.65% | 2019 | |
| Individual | 50–66.65% | 50–66.65% | 2019 | |
| Individual | 25–33.32% | 25–33.32% | 2001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ONCOTYPE ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Andreas Stakemann | Management | 0 companies |
| Theis Barenkopf Dinesen | Management | 0 companies |